Can Midostaurin be used in AML with ASXL1 mutations?

Midostaurin is a multi-target tyrosine kinase inhibitor initially approved for the treatment of patients with acute myeloid leukemia (AML) who have FLT3 mutations. Clinically, it is mainly targeted at FLT3-ITD or FLT3-TKD mutation-positive AML patients. It can be used in combination with standard chemotherapy (such as the DA regimen) to prolong event-free survival and overall survival. Its efficacy has been fully verified in patients with AML with FLT3 mutations.

However, for AMLassociated with ASXL1 mutations, there are currently no sufficient clinical studies or guidelines to clearly support the exact efficacy of midostaurin. ASXL1 is an epigenetic regulation-related gene. Its mutations are common in high-risk AML, myelodysplastic syndrome (MDS) and chronic myeloproliferative diseases, and indicate a poor prognosis. ASXL1 mutation is not the main target of midostaurin, so even if a patient also has ASXL1 mutation, but lacks FLT3 mutation, the benefit of using midostaurin may be very limited.

In clinical practice, patients with AML who have ASXL1 mutations but not FLT3 mutations are usually more inclined to use allogeneic hematopoietic stem cell transplantation or participate in clinical trials to find new treatment pathways. Although there are studies exploring the possible role of midostaurin in combination with other drugs in ASXL1 mutated AML, there is not enough evidence at this stage to recommend it as a standard treatment drug.

To sum up, midostaurin is currently mainly suitable for patients with AML with FLT3 mutations. For AML with ASXL1 mutation, if not mergedFLT3 mutation, the clinical basis for using midostaurin is weak. It is recommended that patients choose individualized treatment plans based on genetic testing results under the guidance of professional hematologists, and participate in relevant clinical studies to explore more suitable targeted drugs when necessary.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html